Literature DB >> 2551924

Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus.

P L Schwimmbeck1, T Dyrberg, D B Drachman, M B Oldstone.   

Abstract

The large majority of patients with the autoimmune disease myasthenia gravis characteristically have detectable antibodies against the acetylcholine receptor (AChR). We used synthetic peptides to identify antibodies in sera of myasthenia gravis patients reactive with the human acetylcholine receptor (HuAChR) alpha-subunit, residues 160-167. Affinity purification of these antibodies, using the HuAChR alpha-subunit 157-170 peptide immobilized on thiopropyl-Sepharose, yielded IgG antibodies that bound to the native AChR and inhibited the binding of alpha-bungarotoxin to the receptor. The HuAChR alpha-subunit 160-167 peptide demonstrated specific immunological cross-reactivity with a shared homologous domain on herpes simplex virus glycoprotein D, residues 286-293, by both binding and inhibition studies. Thus, HuAChR alpha-subunit, residues 160-167, elicits antibodies in myasthenic patients that binds to the native AChR protein and is capable of eliciting a biologic effect. Immunologic cross-reactivity of this "self" epitope with herpes simplex virus suggest that this virus may be associated with the initiation of some cases of myasthenia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551924      PMCID: PMC329775          DOI: 10.1172/JCI114282

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  T-cell antigenic sites tend to be amphipathic structures.

Authors:  C DeLisi; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

2.  Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. Possible role in the pathogenesis of myasthenia gravis.

Authors:  K Stefansson; M E Dieperink; D P Richman; C M Gomez; L S Marton
Journal:  N Engl J Med       Date:  1985-01-24       Impact factor: 91.245

3.  Myosin: a link between streptococci and heart.

Authors:  K Krisher; M W Cunningham
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

4.  Binding affinities of anti-acetylcholine receptor autoantibodies in myasthenia gravis.

Authors:  J J Bray; D B Drachman
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

5.  Attempts to implicate viruses in myasthenia gravis.

Authors:  T Aoki; D B Drachman; D M Asher; C J Gibbs; S Bahmanyar; J S Wolinsky
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

6.  Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

7.  Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products.

Authors:  G P Rice; R D Schrier; M B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

8.  Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor.

Authors:  M Noda; Y Furutani; H Takahashi; M Toyosato; T Tanabe; S Shimizu; S Kikyotani; T Kayano; T Hirose; S Inayama
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

9.  Possible role for a human adenovirus in the pathogenesis of celiac disease.

Authors:  M F Kagnoff; R K Austin; J J Hubert; J E Bernardin; D D Kasarda
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  Epitopes of streptococcal M proteins shared with cardiac myosin.

Authors:  J B Dale; E H Beachey
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

View more
  25 in total

1.  Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Authors:  Rozen Le Panse; Géraldine Cizeron-Clairac; Jacky Bismuth; Sonia Berrih-Aknin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Autoimmune disease and the nervous system.

Authors:  L Steinman
Journal:  West J Med       Date:  1992-06

Review 3.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

Review 4.  Molecular mimicry--hypothesis or reality?

Authors:  N Tsuchiya; R C Williams
Journal:  West J Med       Date:  1992-08

Review 5.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

Review 6.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 7.  Virus-induced autoimmunity: molecular mimicry as a route to autoimmune disease.

Authors:  M B Oldstone
Journal:  J Autoimmun       Date:  1989-06       Impact factor: 7.094

8.  Localization of autoepitopes on the PCM-1 autoantigen using scleroderma sera with autoantibodies against the centrosome.

Authors:  L Bao; C E Varden; W E Zimmer; R Balczon
Journal:  Mol Biol Rep       Date:  1998-03       Impact factor: 2.316

9.  Two short autoepitopes on the nuclear dot antigen are similar to epitopes encoded by the Epstein-Barr virus.

Authors:  K Xie; M Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection.

Authors:  S Eddy; R Wim; V E Peter; R Tanja; T Jan; V S Werner
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.